It reduces stomach-acid production, helping the oesophagus heal and easing acid-related heartburn. Dexilant is intended for people with acid-related upper gastrointestinal conditions.
It reduces stomach-acid production, helping the oesophagus heal and easing acid-related heartburn. Dexilant is intended for people with acid-related upper gastrointestinal conditions.
Dexilant is taken by mouth as a modified-release capsule for gastro-oesophageal reflux disease and erosive oesophagitis.
Dexilant is used for conditions in which stomach acid irritates or damages the oesophagus. Regulatory information for dexlansoprazole supports its use in the following settings:
GORD can involve burning behind the breastbone, sour-tasting reflux, regurgitation, throat irritation or symptoms that worsen after lying down. Erosive oesophagitis may cause painful swallowing or difficulty swallowing, although some people have little discomfort despite visible inflammation.
Dexilant does not provide immediate neutralisation of acid in the same way as a short-acting antacid. It works by reducing acid secretion over time.
| Treatment type | Main action | Usual clinical role |
|---|---|---|
| Short-acting antacid | Neutralises acid already present | Brief relief of occasional symptoms |
| Dexilant and other PPIs | Reduces gastric acid production | GORD, erosive oesophagitis and acid-related healing |
The National Institute for Health and Care Excellence (NICE) recognises PPIs as a central treatment option for GORD and dyspepsia when acid suppression is clinically appropriate [1].
Dexilant contains dexlansoprazole, a proton pump inhibitor (PPI). PPIs reduce acid secretion by blocking the gastric proton pump, an enzyme system in the stomach lining responsible for releasing hydrogen ions into stomach contents.
The medicine is intended for acid-related upper gastrointestinal conditions, including healing erosive oesophagitis and controlling heartburn associated with gastro-oesophageal reflux disease (GORD). Its clinical role differs from a simple antacid: an antacid neutralises acid already present, while dexlansoprazole reduces the production of new acid.
Dexilant uses a Dual Delayed-Release Technology. The capsule releases dexlansoprazole in two phases, helping maintain acid suppression across a longer part of the day than a single immediate-release release can provide. This release pattern is one reason the capsule should be swallowed according to the prescribed instructions rather than crushed.
Dexlansoprazole is absorbed and then reaches the acid-producing cells of the stomach through the bloodstream. It binds to the gastric H+/K+-ATPase, commonly called the proton pump, and suppresses the final stage of acid secretion.
PPIs do not work by coating the oesophagus or mechanically blocking reflux. They reduce acidity, which gives irritated tissue a less damaging environment in which to recover. Reflux can still occur even when its acidity is lower.
The FDA prescribing information (2022) describes proton-pump inhibition as a pharmacological effect that can alter gastric pH and influence the absorption of medicines that depend on stomach acidity [2].
Dexilant is taken orally as a modified-release capsule. The chosen strength and regimen must be confirmed with a healthcare professional before starting.
Administration follows these practical principles:
The capsule can be taken with or without food under the product’s prescribing instructions. Keeping the dose at a consistent time can make missed doses less likely, especially when the medicine is being used for a healing course rather than occasional symptom control.
A common mistake is stopping as soon as heartburn improves. Symptom relief can occur before inflamed oesophageal tissue has fully healed, so the duration of treatment depends on the diagnosis and the regimen selected for the patient.
Dexilant is an oral modified-release capsule that reduces stomach-acid production, unlike lifestyle measures alone, which do not directly reduce acid.
Several habits can reduce the benefit of Dexilant or increase avoidable risk:
One subtle issue concerns terminology. A PPI reduces acid; it does not stop the physical movement of stomach contents into the oesophagus. Persistent regurgitation despite less burning may therefore need a different clinical assessment.
Dexilant is not suitable for everyone. The medicine should not be used by a person with a known hypersensitivity to dexlansoprazole, other substituted benzimidazoles or any capsule ingredient.
Dexilant should not be started without a specific clinical review when any of these apply:
Alarm symptoms require prompt medical assessment. Black stools, vomiting blood, fainting, progressive swallowing difficulty, severe chest pain or sudden unexplained weight loss should not be managed by simply increasing acid suppression.
Common adverse effects reported with dexlansoprazole and other PPIs include headache, diarrhoea, abdominal discomfort, nausea, flatulence and constipation. These effects are often mild, but persistent diarrhoea needs attention because PPI treatment can be associated with Clostridioides difficile-associated diarrhoea.
Seek urgent medical help for facial swelling, wheezing, widespread blistering rash, severe skin peeling or difficulty breathing. These symptoms can indicate a serious allergic or skin reaction.
Longer treatment requires a clear reason and periodic review. Prolonged PPI exposure has been associated with:
These associations do not mean that every long-term user will develop a complication. The decision to continue treatment depends on the strength of the indication, recurrence of symptoms and individual risk factors. The US Food and Drug Administration (FDA) prescribing information lists these warnings and monitoring considerations for dexlansoprazole [3].
A practical detail is often missed: acid suppression can improve burning while a different problem continues underneath. New swallowing difficulty or food sticking is a reason for assessment, not a reason to keep increasing the dose independently.
Clinicians generally select a PPI when acid exposure is causing symptoms, mucosal injury or both. Dexilant can be useful when symptoms extend into the evening or return despite a simpler dosing pattern, though response still varies between patients.
A doctor will usually separate three issues:
In clinical practice, patients sometimes describe partial improvement within several days, while healing of erosive oesophagitis takes longer. A lack of improvement may indicate poor adherence, non-acid reflux, a motility disorder, an ulcer, medication-related irritation or another diagnosis.
The World Health Organization emphasises medication review, appropriate indication and monitoring when medicines are used over an extended period [4]. The chosen strength and regimen should be confirmed with a healthcare professional before treatment begins, rather than selected solely by symptom intensity.
Dexilant is designed to provide acid suppression through a dual delayed-release profile rather than a brief neutralising effect. The clinical effect can extend across much of the day, although symptom control differs between individuals. The FDA prescribing information (2022) describes the delayed-release mechanism and pharmacodynamic action of dexlansoprazole. Relief from burning does not prove that oesophageal healing is complete. Follow the prescribed treatment duration even when symptoms improve.
Some people notice less heartburn within the first few days, while healing of erosive oesophagitis takes longer. NICE guidance published in 2014 describes PPIs as treatment for reflux symptoms and oesophageal healing, with review based on response and diagnosis. Persistent symptoms, new swallowing difficulty or worsening pain require clinical assessment rather than repeated self-dosing.
Diarrhoea is a recognised adverse effect of PPI treatment, and persistent watery diarrhoea can signal Clostridioides difficile infection. The MHRA safety information published in 2012 about antibiotic-associated and healthcare-associated C. difficile diarrhoea remains relevant when acid suppression is present. Contact a healthcare professional promptly if diarrhoea is severe, persistent, bloody or accompanied by fever.
Take the missed capsule when remembered unless the next scheduled dose is due soon. In that situation, skip the missed dose and continue with the normal schedule. The FDA prescribing information (2022) supports avoiding a double dose after an omission. Vomiting, severe abdominal pain or accidental repeated dosing requires specific medical advice.
The combination may be possible in some patients, but warfarin and digoxin require medicine-specific review. The FDA prescribing information (2022) identifies interaction and monitoring considerations for medicines affected by changes in gastric acidity or altered metabolism. Magnesium-containing supplements can also complicate interpretation when a patient has low magnesium or kidney disease, so the complete supplement list should be reviewed before starting.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 3 reviews
The burning after dinner had settled by the first week, and I stopped waking with a sour taste. I still had mild bloating at times, so it was helpful but not completely symptom-free.
Milton Keynes Four weeks 30 Sept 2026I noticed less heartburn after several days. I missed one dose during a weekend away and took two together the next morning, which gave me stomach discomfort. I later followed the missed-dose advice instead.
Southampton Three weeks 12 Oct 2026The pain when swallowing improved gradually rather than overnight. I had loose stools for a few days and reported them because they continued; the treatment plan was then reviewed.
Coventry Several weeks 27 Oct 2026
